First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
Status:
Completed
Trial end date:
2018-08-28
Target enrollment:
Participant gender:
Summary
The phase I dose escalation study will investigate the safety, tolerability, and
pharmacokinetics of the TGF-β pathway inhibitor TEW 7197 in subjects with advanced,
refractory solid tumors.